# Weekly cases\* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending November 4, 2023 (Week 44)

(Accessible Version: https://wonder.cdc.gov//nndss/static/2023/44/2023-44-table355.html)

Reporting Area	Carbapenemase-Producing Organisms (CPO), Total §,¶				
	Current week	Previous 52 weeks Max +	Cum YTD 2023 +	Cum YTD 2022 +	
U.S. Residents, excluding U.S. Territories	102	NC	5,037	NN	
New England	-	NC	47	NN	
Connecticut	-	NC	-	NN	
Maine	-	NC	-	NN	
Massachusetts	-	NC	-	NN	
New Hampshire	-	NC	18	NN	
Rhode Island	-	NC	29	NN	
Vermont	-	NC	-	NN	
Middle Atlantic	5	NC	573	NN	
New Jersey	-	NC	-	NN	
New York (excluding New York City)	-	NC	-	NN	
New York City	-	NC	145	NN	
Pennsylvania	5	NC	428	NN	
East North Central	65	NC	1,661	NN	
Illinois	-	NC	58	NN	
Indiana	-	NC	276	NN	
Michigan	2	NC	182	NN	
Ohio	63	NC	1,115	NN	
Wisconsin	-	NC	30	NN	
West North Central	-	NC	89	NN	
lowa	-	NC	65	NN	
Kansas	-	NC	17	NN	
Minnesota	-	NC	-	NN	
Missouri	-	NC	-	NN	
Nebraska	-	NC	-	NN	
North Dakota	-	NC	7	NN	
South Dakota	-	NC	-	NN	
South Atlantic	4	NC	566	NN	
Delaware	-	NC	3	NN	
District of Columbia	-	NC	-	NN	
Florida	N	NC	N	NN	
Georgia	-	NC	196	NN	
Maryland	-	NC	-	NN	
North Carolina	-	NC	116	NN	
South Carolina	-	NC	-	NN	
Virginia	4	NC	210	NN	
West Virginia	-	NC	41	NN	
East South Central	-	NC	34	NN	
Alabama	N	NC	N	NN	
Kentucky	-	NC		NN	
Mississippi		NC	34	NN	
Tennessee	_	NC		NN	
West South Central	-	NC	17	NN	
Arkansas	_	NC		NN	
Louisiana	_	NC	17	NN	
Oklahoma	_	NC		NN	
Texas		NC		NN	
Mountain	1	NC	610	NN	
Arizona	1	NC	593	NN	
Colorado	-	NC	-	NN	
Idaho		NC		NN	
Montana	-	NC		NN	
Nevada	-	NC	2	NN	

## Weekly cases\* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending November 4, 2023 (Week 44)

(Accessible Version: https://wonder.cdc.gov//nndss/static/2023/44/2023-44-table355.html)

Reporting Area	Carbapenemase-Producing Organisms (CPO), Total §,¶				
	Current week	Previous 52 weeks Max +	Cum YTD 2023 +	Cum YTD 2022 +	
New Mexico	-	NC	-	NN	
Utah	-	NC	15	NN	
Wyoming	-	NC	-	NN	
Pacific	27	NC	1,440	NN	
Alaska	-	NC	-	NN	
California	27	NC	1,409	NN	
Hawaii	-	NC	5	NN	
Oregon	-	NC	19	NN	
Washington	-	NC	7	NN	
U.S. Territories	-	NC	20	NN	
American Samoa	-	NC	-	NN	
Commonwealth of Northern Mariana Islands	-	NC	-	NN	
Guam	-	NC	-	NN	
Puerto Rico	-	NC	20	NN	
U.S. Virgin Islands	-	NC	-	NN	
Non-U.S. Residents	-	NC	-	NN	
Total	102	NC	5,057	NN	

U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.

-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.

N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.

NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.

NP: Nationally notifiable but not published.

NC: Not calculated — There is insufficient data available to support the calculation of this statistic.

Cum: Cumulative year-to-date counts.

\* Case counts for reporting years 2022 and 2023 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/data-statistics/readers-guides/.

+ Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).

§ Beginning in January 2023, cases began to be reported as Carbapenemase-Producing Organisms, clinical or Carbapenemase-Producing Organisms, screening. In previous years, only Carbapenemase-Producing Carbapenem-Resistant *Enterobacteriaceae* (CP-CRE) cases were reported.
¶ CPO (total) is the sum of CP-CRE cases reported in MMWR year 2023, CPO clinical cases, and CPO screening cases.

#### Notes:

- These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly in alphabetical order by condition. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented *as published* each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
- Weekly tables since 1996 are available on CDC WONDER.
- Weekly tables since 2014 are available on Data.CDC.gov.
- Weekly tables for 1952–2017 published in the Morbidity and Mortality Weekly Reports (MMWR) are available at CDC Stacks MMWR, and weekly tables starting in 2018 are available at CDC Stacks NNDSS (once in CDC Stacks NNDSS select "Weekly Tables" in the "Genre" box at the left).
- Notices, errata, and other notes are available in the Notice To Data Users page.
- The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

#### Suggested Citation:

• Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, Weekly Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance. Available at: https://www.cdc.gov/nndss/data-statistics/index.html.

### Acknowledgment:

• CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., health-care providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.

#### National Notifiable Diseases Surveillance System